Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-17 Years According to Different Vaccination Schedules

NCT00661713 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00661713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00661713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-17 Years According to Different Vaccination Schedules
Lead sponsor
Novartis Vaccines
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 2008
Completion date
December 31, 2010
Enrollment
1,631 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease